Skip to main content

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset.

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

Filter results

You can narrow down the results using the filters

Sponsor

Search

897 result(s) found, displaying 1 to 25
  • AusPAR: Zeposia

    AusPAR for Zeposia (ozanimod) for the treatment of adult patients with moderately to severely active ulcerative colitis.
  • AusPAR: Libtayo

    New AusPAR for LIBTAYO (cemiplimab) as first-line treatment of adult patients with non-small cell lung cancer.
  • AusPAR: Brukinsa

    Brukinsa (zanubrutinib) for the treatment of of adult patients with Waldenström’s macroglobulinaemia
  • AusPAR: Pegcetacoplan

    New AusPAR for Empaveli (pegcetacoplan) for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria.
  • AusPAR: Brukinsa

    Brukinsa (zanubrutinib) for the treatment of adult patients with mantle cell lymphoma
  • AusPAR: Tecentriq

    New AusPAR for Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer.
  • AusPAR: Tepmetko

    Tepmetko (tepotinib) for treatment of non-small cell lung cancer with MET exon 14 skipping alterations.
  • AusPAR: Spikevax

    Spikevax (elasomeran) for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older
  • AusPAR: Nuvaxovid

    Nuvaxovid (SARS-CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for prevention of COVID-19 in individuals 12 years of age and older.
  • AusPAR: Nextstellis

    Nextstellis (estetrol monohydrate and drospirenone) for the prevention of pregnancy
  • AusPAR: Verquvo

    New AusPAR for Verquvo (vericiguat) as addition to standard of care therapy for the treatment of symptomatic chronic heart failure.
  • AusPAR: Tivicay and Tivicay PD

    TIVICAY (dolutegravir ) for treatment of HIV infection in combination with other antiretroviral agents.
  • AusPAR: Crysvita

    Crysvita (burosumab) for the treatment of X-linked hypophosphataemia (XLH)
  • AusPAR: Nuvaxovid heterologous booster

    Nuvaxovid heterologous booster (CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for the prevention of COVID-19.
  • AusPAR: Trastuzumab deruxtecan

    Enhertu (trastuzumab deruxtecan) for treatment of unresectable or metastatic HER2 positive breast cancer.
  • AusPAR: Nuvaxovid homologous booster

    Nuvaxovid homologous booster (CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for the prevention of COVID-19.
  • AusPAR: VeraSeal

    VeraSeal (human fibrinogen and human thrombin) for the supportive treatment of hemostasis.
  • AusPAR: Finerenone

    Kerendia (finerenone) for the treatment of progressive decline of kidney function in adults.
  • AusPAR: Bevacizumab

    Bevacip/Bevaciptin (bevacizumab) for the treatment of types of cancer.
  • AusPAR: Deutetrabenazine

    AUSTEDO (deutetrabenazine) for the treatment of chorea associated with Huntington's disease and tardive dyskinesia in adult.
  • AusPAR: Remdesivir

    New AusPAR for VEKLURY (remdesivir ) for the treatment of coronavirus disease 2019 in paediatric and adult patients.
  • AusPAR: Belumosudil

    New AusPAR for Rholistiq (belumosudil) for the treatment of patients with chronic graft-versus-host disease aged 12 years and older.
  • AusPAR: Luspatercept

    Australian Public Assessment Report for Luspatercept

Help us improve the Therapeutic Goods Administration site